open access

Vol 13, No 2 (2020)
Review paper
Published online: 2020-10-05
Get Citation

Platelet-rich plasma therapy (PRP) – a promising method of regenerative treatment of damaged tissues used in many fields of medicine

Łukasz Piszczorowicz, Dorota Król, Stanisław Dyląg
Journal of Transfusion Medicine 2020;13(2):120-134.

open access

Vol 13, No 2 (2020)
REVIEWS
Published online: 2020-10-05

Abstract

Platelet-rich plasma (PRP) therapy is widely used in many fields of medicine and is becoming more and more popular in the treatment of many diseases. Platelets (PLT) contain physiologically active proteins called growth factors (GFs) that accelerate the regeneration of damaged tissue. Stimulation of regeneration of damaged tissue is possible thanks to the use of patient's own blood, which must be properly prepared before administration. PRP preparation consists in concentrating the PLT several times in relation to the patient's peripheral blood. Because the treatment is based on autologous transfusion, the risk of adverse reactions is negligible, although in some situations some risk factors limit the use of PRP and may contribute to the occurrence of adverse effects. Preparation is relatively cheap and quick and can be carried out in the presence of a patient. In the literature can be found different definitions of PRP, methods of preparation, concentrations of PLT, ways of activating PLT, ways of administering PRP to damaged tissue, and finally different effects of treatment with this blood derivative. In addition, confirming the effectiveness of PRP therapy is difficult, comparing the treatment of various diseases with each other. The authors clearly emphasize the need for standardization of preparation and administration of PRP in various diseases. The lack of harmonization of preparation procedures and the way of administering PRP raises many questions and controversies, although PRP therapy is considered a promising method of treating tissue injuries. The aim of this article is to show what lies behind the concept of PRP, what is its mechanism of action as well as to show and systematize the complexity of PRP issues.

Abstract

Platelet-rich plasma (PRP) therapy is widely used in many fields of medicine and is becoming more and more popular in the treatment of many diseases. Platelets (PLT) contain physiologically active proteins called growth factors (GFs) that accelerate the regeneration of damaged tissue. Stimulation of regeneration of damaged tissue is possible thanks to the use of patient's own blood, which must be properly prepared before administration. PRP preparation consists in concentrating the PLT several times in relation to the patient's peripheral blood. Because the treatment is based on autologous transfusion, the risk of adverse reactions is negligible, although in some situations some risk factors limit the use of PRP and may contribute to the occurrence of adverse effects. Preparation is relatively cheap and quick and can be carried out in the presence of a patient. In the literature can be found different definitions of PRP, methods of preparation, concentrations of PLT, ways of activating PLT, ways of administering PRP to damaged tissue, and finally different effects of treatment with this blood derivative. In addition, confirming the effectiveness of PRP therapy is difficult, comparing the treatment of various diseases with each other. The authors clearly emphasize the need for standardization of preparation and administration of PRP in various diseases. The lack of harmonization of preparation procedures and the way of administering PRP raises many questions and controversies, although PRP therapy is considered a promising method of treating tissue injuries. The aim of this article is to show what lies behind the concept of PRP, what is its mechanism of action as well as to show and systematize the complexity of PRP issues.
Get Citation

Keywords

platelet-rich plasma (PRP); PRP preparation; platelets (PLT); growth factors (GFs); tissue regeneration

About this article
Title

Platelet-rich plasma therapy (PRP) – a promising method of regenerative treatment of damaged tissues used in many fields of medicine

Journal

Journal of Transfusion Medicine

Issue

Vol 13, No 2 (2020)

Article type

Review paper

Pages

120-134

Published online

2020-10-05

Bibliographic record

Journal of Transfusion Medicine 2020;13(2):120-134.

Keywords

platelet-rich plasma (PRP)
PRP preparation
platelets (PLT)
growth factors (GFs)
tissue regeneration

Authors

Łukasz Piszczorowicz
Dorota Król
Stanisław Dyląg

References (94)
  1. Alves R, Grimalt R. A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification. Skin Appendage Disord. 2018; 4(1): 18–24.
  2. Kohler N, Lipton A. Platelets as a source of fibroblast growth-promoting activity. Exp Cell Res. 1974; 87(2): 297–301.
  3. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. 2004; 114(6): 1502–1508.
  4. Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008; 16(5): 585–601.
  5. Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci. 2010; 86(6): 588–610.
  6. Ferrari M, Zia S, Valbonesi M, et al. A new technique for hemodilution, preparation of autologous platelet-rich plasma and intraoperative blood salvage in cardiac surgery. Int J Artif Organs. 2018; 10(1): 47–50.
  7. Tayapongsak P, O'Brien D, Monteiro C, et al. Autologous fibrin adhesive in mandibular reconstruction with particulate cancellous bone and marrow. J Oral Maxillofac Surg. 1994; 52(2): 161–165.
  8. Whitman DH, Berry RL, Green DM. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg. 1997; 55(11): 1294–1299.
  9. Taniguchi Yu, Yoshioka T, Sugaya H, et al. Growth factor levels in leukocyte-poor platelet-rich plasma and correlations with donor age, gender, and platelets in the Japanese population. J Exp Orthop. 2019; 6(1): 4.
  10. Evans LA, Morey AF. Current applications of fibrin sealant in urologic surgery. Int Braz J Urol. 2006; 32(2): 131–141.
  11. de Vos RJ, Weir A, van Schie HTM, et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA. 2010; 303(2): 144–149.
  12. Sánchez M, Anitua E, Azofra J, et al. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med. 2007; 35(2): 245–251.
  13. Mlynarek RA, Kuhn AW, Bedi A. Platelet-rich plasma (PRP) in orthopedic sports medicine. Am J Orthop 2016;45(5):290-326. PMID. : 27552452.
  14. Gholami M, Ravaghi H, Salehi M, et al. A systematic review and meta-analysis of the application of platelet rich plasma in sports medicine. Electron Physician. 2016; 8(5): 2325–2332.
  15. Dohan Ehrenfest DM, Bielecki T, Mishra A, et al. In search of a consensus terminology in the field of platelet concentrates for surgical use: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. Curr Pharm Biotechnol. 2012; 13(7): 1131–1137.
  16. Cohn CS, Lockhart E. Autologous platelet-rich plasma: evidence for clinical use. Curr Opin Hematol. 2015; 22(6): 527–532.
  17. Duong QV, Kintzing ML, Kintzing WE, et al. Plasma Rich in Growth Factors (PRGF) Disrupt the Blood-Brain Barrier Integrity and Elevate Amyloid Pathology in the Brains of 5XFAD Mice. Int J Mol Sci. 2019; 20(6).
  18. Mehta S, Watson JT. Platelet rich concentrate: basic science and current clinical applications. J Orthop Trauma. 2008; 22(6): 432–438.
  19. Kawase T, Tanaka T. An updated proposal for terminology and classification of platelet-rich fibrin. Regen Ther. 2017; 7: 80–81.
  20. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001; 10(4): 225–228.
  21. Jungbluth P, Wild M, Grassmann JP, et al. Platelet-rich plasma on calcium phosphate granules promotes metaphyseal bone healing in mini-pigs. J Orthop Res. 2010; 28(11): 1448–1455.
  22. Cho JM, Lee YHo, Baek RM, et al. Effect of platelet-rich plasma on ultraviolet b-induced skin wrinkles in nude mice. J Plast Reconstr Aesthet Surg. 2011; 64(2): e31–e39.
  23. Franchini M, Dupplicato P, Ferro I, et al. Efficacy of Platelet Gel in Reconstructive Bone Surgery. Orthopedics. 2005; 28(2): 161–163.
  24. Anitua E, Andia I, Ardanza B, et al. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004; 91(1): 4–15.
  25. Graziani F, Ivanovski S, Cei S, et al. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res. 2006; 17(2): 212–219.
  26. Weibrich G, Hansen T, Kleis W, et al. Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone. 2004; 34(4): 665–671.
  27. Oudelaar BW, Peerbooms JC, Huis In 't Veld R, et al. Concentrations of Blood Components in Commercial Platelet-Rich Plasma Separation Systems: A Review of the Literature. Am J Sports Med. 2019; 47(2): 479–487.
  28. Castillo TN, Pouliot MA, Kim HJ, et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2011; 39(2): 266–271.
  29. Ehrenfest DMD, Andia I, Zumstein MA, et al. Classification of platelet concentrates (platelet-rich plasma-PRP, platelet-rich fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscle Ligaments and Tendons Journal. 2019; 04(01): 03.
  30. Gołos A, Treliński J. Clinical applications of platelet-rich plasma. Hematologia 2014;5(3):252-9. [Google Scholar].
  31. Jameson C. Autologous Platelet Concentrate for the Production of Platelet Gel. Laboratory Medicine. 2007; 38(1): 39–42.
  32. Floryan KM, Berghoff WJ. Intraoperative use of autologous platelet-rich and platelet-poor plasma for orthopedic surgery patients. AORN J. 2004; 80(4): 668–74, quiz 675.
  33. Moradi O, Seyyed MG, Mohammad MD, Sedaghat R, Akbarein H. Effects of platelet rich plasma (PRP) and platelet rich growth factor (PRGF®) on the wound healing of distal part of limbs in horses. IJVS 2013;8(1):41-7. [Google Scholar].
  34. Fanning J, Murrain L, Flora R, et al. Phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery. J Minim Invasive Gynecol. 2007; 14(5): 633–637.
  35. Wrotniak M, Bielecki T, Gaździk TS. Current opinion about using the platelet-rich gel in orthopaedics and trauma surgery. Ortop Traumatol Rehabil 2007;3(6):227-38. [Google Scholar].
  36. Alissa R, Esposito M, Horner K, et al. The influence of platelet-rich plasma on the healing of extraction sockets: an explorative randomised clinical trial. Eur J Oral Implantol 2010;3(2):121-34. PMID. : 20623037.
  37. Moraes VY, Lenza M, Tamaoki MJ, et al. Platelet-rich therapies for musculoskeletal soft tissue injuries. Cochrane Database Syst Rev. 2013(12): CD010071.
  38. Elghblawi E. Medical micro-needling. Trichol Cosmetol Open J 2017;1(1):21-4. DOI: 10.17140/TCOJ-1-105.
  39. Sand JP, Nabili V, Kochhar A, et al. Platelet-Rich Plasma for the Aesthetic Surgeon. Facial Plast Surg. 2017; 33(4): 437–443.
  40. Chomicki-Bindas P, Zakrzewski P, Pomianowski S. Platelet concentrates, as new and promising agent in the orthopedic surgery – an introduction. Borgis - Post Nauk Med 2010;23(2):153-7. [Reflink].
  41. Bielecki T, Gaździk TS, Cieślik-Bielecka A, Cieślik T. Application of the platelet rich plasma as biomaterial stimulating tissue regeneration and reparation processes. Inż Biomater 2004;7(34):22-5. [Google Scholar].
  42. Roffi A, Filardo G, Assirelli E, et al. Does platelet-rich plasma freeze-thawing influence growth factor release and their effects on chondrocytes and synoviocytes? Biomed Res Int. 2014; 2014: 692913.
  43. Lubkowska A, Dołęgowska B, Banfi G. Growth factor content in PRP and their applicability in medicine. J Biol Regul Homeost Agents 2012;26(2):3-22. PMID. : 23648195.
  44. ten Dijke P, Hansen P, Iwata KK, et al. Identification of another member of the transforming growth factor type beta gene family. Proc Natl Acad Sci U S A. 1988; 85(13): 4715–4719.
  45. Houde N, Chamoux E, Bisson M, et al. Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim. J Biol Chem. 2009; 284(35): 23397–23404.
  46. Tran J, Rak J, Sheehan C, et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun. 1999; 264(3): 781–788.
  47. Bielawska L, Kopczyński P, Szubińska P, Baszczuk A, Kopczyński Z. Evaluation of release rate of vascular endothelial growth factor (VEGF) by activated in vitro platelets in platelet-rich plasma. Post Nauk Med 2014;27(12B):5-10. [docplayer].
  48. Alsousou J, Thompson M, Hulley P, et al. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br. 2009; 91(8): 987–996.
  49. Krüger JP, Freymannx U, Vetterlein S, et al. Bioactive factors in platelet-rich plasma obtained by apheresis. Transfus Med Hemother. 2013; 40(6): 432–440.
  50. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004; 62(4): 489–496.
  51. Wang C, Xu M, Guo W, et al. Clinical efficacy and safety of platelet-rich plasma in arthroscopic full-thickness rotator cuff repair: A meta-analysis. PLoS One. 2019; 14(7): e0220392.
  52. Kour P, Pudakalkatti PS, Vas AM, et al. Comparative Evaluation of Antimicrobial Efficacy of Platelet-rich Plasma, Platelet-rich Fibrin, and Injectable Platelet-rich Fibrin on the Standard Strains of and . Contemp Clin Dent. 2018; 9(Suppl 2): S325–S330.
  53. Drago L, Bortolin M, Vassena C, et al. Plasma components and platelet activation are essential for the antimicrobial properties of autologous platelet-rich plasma: an in vitro study. PLoS One. 2014; 9(9): e107813.
  54. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun. 2002; 70(12): 6524–6533.
  55. Cieślik-Bielecka A, Bold T, Ziółkowski G, et al. Antibacterial Activity of Leukocyte- and Platelet-Rich Plasma: An Study. Biomed Res Int. 2018; 2018: 9471723.
  56. Mochizuki T, Yano K, Ikari K, et al. Platelet-rich plasma for the reduction of blood loss after total knee arthroplasty: a clinical trial. Eur J Orthop Surg Traumatol. 2016; 26(8): 901–905.
  57. Tian WZ, Er JX, Liu L, et al. Effects of Autologous Platelet Rich Plasma on Intraoperative Transfusion and Short-Term Outcomes in Total Arch Replacement (Sun's Procedure): A Prospective, Randomized Trial. J Cardiothorac Vasc Anesth. 2019; 33(8): 2163–2169.
  58. Johal H, Khan M, Yung SHP, et al. Impact of Platelet-Rich Plasma Use on Pain in Orthopaedic Surgery: A Systematic Review and Meta-analysis. Sports Health. 2019; 11(4): 355–366.
  59. Rutkowski J, Thomas J, Bering C, et al. An Analysis of a Rapid, Simple, and Inexpensive Technique Used to Obtain Platelet-Rich Plasma for Use in Clinical Practice. Journal of Oral Implantology. 2008; 34(1): 25–33.
  60. Buchholz DH, Young VM, Friedman NR, et al. Bacterial proliferation in platelet products stored at room temperature. Transfusion-induced Enterobacter sepsis. N Engl J Med. 1971; 285(8): 429–433.
  61. Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. Curr Rev Musculoskelet Med. 2008; 1(3-4): 165–174.
  62. Everts PAM, Knape JTA, Weibrich G, et al. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006; 38(2): 174–187.
  63. Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood. 1990; 76(10): 2011–2016.
  64. Ciążyńska M, Bednarski I, Lesiak A. The role of TGF-β in photodegradation and carcinogenesis. Forum Dermatologicum 2016;2(2):60-3. [Google Scholar].
  65. Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011; 39(10): 2135–2140.
  66. Tidball JG. Inflammatory cell response to acute muscle injury. Med Sci Sports Exerc. 1995; 27(7): 1022–1032.
  67. Šumanovac A. Platelet-rich plasma in orthopaedics – to use or not to use? Orthopedics, Traumatology Spor Med Int J. 2018; 1(1): 5–6.
  68. Miron RJ, Fujioka-Kobayashi M, Bishara M, et al. Platelet-Rich Fibrin and Soft Tissue Wound Healing: A Systematic Review. Tissue Eng Part B Rev. 2017; 23(1): 83–99.
  69. Chen JX, Justicz N, Lee LN. Platelet-Rich Plasma for the Treatment of Androgenic Alopecia: A Systematic Review. Facial Plast Surg. 2018; 34(6): 631–640.
  70. Chang Y, Li J, Chen Y, et al. Autologous platelet-rich plasma promotes endometrial growth and improves pregnancy outcome during in vitro fertilization. Int J Clin Exp Med 2015;8(1):1286-90. PMCID. : PMC4358582.
  71. Malahias MA, Chytas D, Mavrogenis AF, et al. Platelet-rich plasma injections for carpal tunnel syndrome: a systematic and comprehensive review. Eur J Orthop Surg Traumatol. 2019; 29(1): 1–8.
  72. Di Mario A, Crescenzi D, Di Rienzo Businco L. Functional reconstruction of turbinates with growth factors and adipose tissue in the treatment of empty nose syndrome. J J Bone Stem Res 2015;1(2):1-9. [Jacobs Publishers].
  73. Jarka E. Review of Sjögren Syndrome: A Comparison of Two Topical Biologic Treatment Options. J Ophthalmol Clin Res. 2016; 3(3): 1–7.
  74. Avila MY, Igua AM, Mora AM. Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye. Br J Ophthalmol. 2018 [Epub ahead of print].
  75. Scott S, Roberts M, Chung E. Platelet-Rich Plasma and Treatment of Erectile Dysfunction: Critical Review of Literature and Global Trends in Platelet-Rich Plasma Clinics. Sex Med Rev. 2019; 7(2): 306–312.
  76. Desai SA, Kroumpouzos G, Sadick N. Vaginal rejuvenation: From scalpel to wands. Int J Womens Dermatol. 2019; 5(2): 79–84.
  77. JB N. O-Shot: Platelets Rich Plasma in Intimate Female Treatment. Journal of Women's Health Care. 2017; 06(05).
  78. Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 101(3): e37–e44.
  79. Cieślik-Bielecka A, Bielecki T, Gaździk TS, Cieślik T. Growth factors in the platelet-rich plasma as autogenic material which stimulates bone healing processes. Czas Stomatol 2006;59(7):510-7. [Google Scholar].
  80. Ogundipe OK, Ugboko VI, Owotade FJ, et al. Preparation of platelet-rich plasma from small volume of whole blood - a simplified approach. Niger Postgrad Med J 2012;19(3):133-6. PMID. : 23064167.
  81. Mishra A, Harmon K, Woodall J, et al. Sports medicine applications of platelet rich plasma. Curr Pharm Biotechnol. 2012; 13(7): 1185–1195.
  82. Du L, Miao Y, Li X, et al. A Novel and Convenient Method for the Preparation and Activation of PRP without Any Additives: Temperature Controlled PRP. Biomed Res Int. 2018; 2018: 1761865.
  83. Harrison S, Vavken P, Kevy S, et al. Platelet activation by collagen provides sustained release of anabolic cytokines. Am J Sports Med. 2011; 39(4): 729–734.
  84. Irmak G, Demirtaş TT, Gümüşderelioğlu M. Sustained release of growth factors from photoactivated platelet rich plasma (PRP). Eur J Pharm Biopharm. 2020; 148: 67–76.
  85. Neculaes VB, Torres AS, Caiafa A, Dun-Lan Lee B, Garner AL. Platelet activation and growth factor release using electric pulses. United States Patent No. US010369200B2. 2019. [patentimages].
  86. Lopez-Vidriero E, Goulding KA, Simon DA, et al. The use of platelet-rich plasma in arthroscopy and sports medicine: optimizing the healing environment. Arthroscopy. 2010; 26(2): 269–278.
  87. Fadadu PP, Mazzola AJ, Hunter CW, et al. Review of concentration yields in commercially available platelet-rich plasma (PRP) systems: a call for PRP standardization. Reg Anesth Pain Med. 2019 [Epub ahead of print].
  88. Chahla J, Cinque ME, Piuzzi NS, et al. A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. J Bone Joint Surg Am. 2017; 99(20): 1769–1779.
  89. DeLong JM, Russell RP, Mazzocca AD. Platelet-rich plasma: the PAW classification system. Arthroscopy. 2012; 28(7): 998–1009.
  90. Mautner K, Malanga GA, Smith J, et al. A call for a standard classification system for future biologic research: the rationale for new PRP nomenclature. PM R. 2015; 7(4 Suppl): S53–S59.
  91. Magalon J, Chateau AL, Bertrand B, et al. DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices. BMJ Open Sport Exerc Med. 2016; 2(1): e000060.
  92. Lana JF, Purita J, Paulus C, et al. Contributions for classification of platelet rich plasma - proposal of a new classification: MARSPILL. Regen Med. 2017; 12(5): 565–574.
  93. Amable PR, Carias RB, Teixeira MV, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013; 4(3): 67.
  94. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009; 27(3): 158–167.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Journal of Transfusion Medicine dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl